Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Willing and able to give written informed consent~2. Confirmed MS diagnosis as defined by the McDonald criteria~3. R-R MS disease course.~4. At least one gadolinium-enhanced lesion on screening MRI~5. Women of child-bearing potential must practice a reliable method of birth control.~6. Must understand the requirements of the study and agree to comply with the study protocol.~Exclusion Criteria:~1. Subjects who suffer from any form of progressive MS.~2. Any condition which the investigator feels may interfere with participation in the study.~3. Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation,~4. Subjects who received any investigational medication, immunosuppressives or cytotoxic agents within 6 months prior to screening~5. Previous treatment with immunomodulators within two months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Laquinimod 0.3 mg (Type: ACTIVE_COMPARATOR): Laquinimod 0.3 mg
- Laquinimod 0.6 mg (Type: ACTIVE_COMPARATOR): Laquinimod 0.6 mg
- Placebo (Type: PLACEBO_COMPARATOR): Blinded Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).